Rznomics Inc.

Rznomics Inc. is a biopharmaceutical startup focused on developing innovative treatments for cancer and intractable diseases through its RNA-based platform technology called trans-splicing ribozyme. Established in 2017, Rznomics has gained recognition from bio-focused institutions and successfully raised a total of KRW 60.9 billion in funding, including a recent KRW 37.2 billion series C investment from Korea Development Bank, Partners Investment, IBK Capital, UTC 2019 BioVentureFund, QUAD Ventures, Shinhan Venture Investment, Aon, and SBI Investment Korea. In 2022 1H, Rznomics achieved a significant milestone with the approval of its RZ-001 IND submission for the HCC treatment by the MFDS, and the clinical trial for RZ-001 is underway. The company also boasts a robust pipeline including treatments for glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology. Additionally, Rznomics is actively engaging in partnerships with global companies to explore opportunities for co-research, co-development, and licensing. Rznomics' dedication to developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease, coupled with its strategic partnerships and substantial funding, positions the company as a promising player in the biopharma and biotechnology industries.